Evolent Health Beheer
Beheer criteriumcontroles 2/4
De CEO Evolent Health is Seth Blackley, benoemd in Jan2011, heeft een ambtstermijn van 13.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.93M, bestaande uit 8.8% salaris en 91.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.27% van de aandelen van het bedrijf, ter waarde $ 3.60M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 4.4 jaar.
Belangrijke informatie
Seth Blackley
Algemeen directeur
US$8.9m
Totale compensatie
| Percentage CEO-salaris | 8.8% |
| Dienstverband CEO | 13.8yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 3.7yrs |
| Gemiddelde ambtstermijn bestuur | 4.4yrs |
Recente managementupdates
Recent updates
Evolent Health: A Shot At Revival After Market Bruising
Nov 12Take Care Before Jumping Onto Evolent Health, Inc. (NYSE:EVH) Even Though It's 49% Cheaper
Nov 09
We Like These Underlying Return On Capital Trends At Evolent Health (NYSE:EVH)
Nov 07Evolent Health (NYSE:EVH) Has A Pretty Healthy Balance Sheet
Sep 19Evolent Health: Let The Bidding Begin
Aug 23Potential Upside For Evolent Health, Inc. (NYSE:EVH) Not Without Risk
Jul 29Evolent Health's (NYSE:EVH) Returns On Capital Are Heading Higher
Jul 01Evolent Health: Recent Pullback, A Buying Opportunity Or Not? (Rating Downgrade)
May 22These 4 Measures Indicate That Evolent Health (NYSE:EVH) Is Using Debt Reasonably Well
May 05Evolent Health, Inc. (NYSE:EVH) Doing What It Can To Lift Shares
Apr 08Evolent Health (NYSE:EVH) Is Experiencing Growth In Returns On Capital
Mar 12Evolent Health (NYSE:EVH) Takes On Some Risk With Its Use Of Debt
Jan 17Many Still Looking Away From Evolent Health, Inc. (NYSE:EVH)
Dec 21Evolent Health (NYSE:EVH) Is Looking To Continue Growing Its Returns On Capital
Nov 30A First Evaluation On Evolent Health
Oct 04Does Evolent Health (NYSE:EVH) Have A Healthy Balance Sheet?
Sep 29There's Been No Shortage Of Growth Recently For Evolent Health's (NYSE:EVH) Returns On Capital
Sep 01An Intrinsic Calculation For Evolent Health, Inc. (NYSE:EVH) Suggests It's 47% Undervalued
Aug 04Evolent Health: Business Economics Still Appealing, Reiterate Buy
Jul 19Cautious Investors Not Rewarding Evolent Health, Inc.'s (NYSE:EVH) Performance Completely
Jun 14Evolent Health (NYSE:EVH) Takes On Some Risk With Its Use Of Debt
May 30An Intrinsic Calculation For Evolent Health, Inc. (NYSE:EVH) Suggests It's 34% Undervalued
May 02Evolent Health (NYSE:EVH) Shareholders Will Want The ROCE Trajectory To Continue
Apr 17Evolent Health GAAP EPS of $0.11 beats by $0.13, revenue of $382.4M beats by $9.47M
Feb 22Is Evolent Health (NYSE:EVH) A Risky Investment?
Feb 19Evolent Health: Strengthening Fundamentals, Investing At High Rates Of Return
Feb 15Is Evolent Health, Inc. (NYSE:EVH) Potentially Undervalued?
Feb 01Evolent Health (NYSE:EVH) Might Have The Makings Of A Multi-Bagger
Jan 14Evolent spikes as Humana partnership expands
Jan 12Is Evolent Health, Inc. (NYSE:EVH) Trading At A 49% Discount?
Dec 27Evolent Health offered $23.5M class action securities settlement
Sep 19Evolent Health's (NYSE:EVH) Returns On Capital Are Heading Higher
Sep 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$104m |
| Jun 30 2024 | n/a | n/a | -US$106m |
| Mar 31 2024 | n/a | n/a | -US$141m |
| Dec 31 2023 | US$9m | US$783k | -US$142m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$77m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$8m | US$683k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$4m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$7m | US$600k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$68m |
| Mar 31 2021 | n/a | n/a | -US$261m |
| Dec 31 2020 | US$4m | US$438k | -US$328m |
| Sep 30 2020 | n/a | n/a | -US$515m |
| Jun 30 2020 | n/a | n/a | -US$504m |
| Mar 31 2020 | n/a | n/a | -US$334m |
| Dec 31 2019 | US$3m | US$400k | -US$304m |
| Sep 30 2019 | n/a | n/a | -US$121m |
| Jun 30 2019 | n/a | n/a | -US$107m |
| Mar 31 2019 | n/a | n/a | -US$86m |
| Dec 31 2018 | US$2m | US$400k | -US$53m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$49m |
| Mar 31 2018 | n/a | n/a | -US$56m |
| Dec 31 2017 | US$2m | US$400k | -US$61m |
Compensatie versus markt: De totale vergoeding ($USD 8.93M ) Seth } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.37M ).
Compensatie versus inkomsten: De vergoeding van Seth is gestegen terwijl het bedrijf verliesgevend is.
CEO
Seth Blackley (45 yo)
13.8yrs
Tenure
US$8,931,188
Compensatie
Mr. Seth Barrie Blackley is Director of Iodine Software, LLC. He serves as Chief Executive Officer at Evolent Health, Inc. since October 1, 2020. He serves as President of True Health Indiana, Inc. (True H...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 13.8yrs | US$8.93m | 0.27% $ 3.6m | |
| President | 2.2yrs | US$5.76m | 0.16% $ 2.2m | |
| Chief Financial Officer | 5.3yrs | US$3.53m | 0.15% $ 2.0m | |
| Chief Operating Officer | 1.3yrs | US$2.69m | 0.055% $ 734.8k | |
| Chief Legal Officer | 10.8yrs | US$2.01m | 0.11% $ 1.4m | |
| Chief Accounting Officer | 4.4yrs | US$634.88k | 0.020% $ 264.5k | |
| Senior Vice President of Corporate Finance | less than a year | geen gegevens | geen gegevens | |
| Chief Technology Officer | no data | geen gegevens | geen gegevens | |
| Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | 2.9yrs | geen gegevens | geen gegevens | |
| Chief Strategy Officer | 12.8yrs | geen gegevens | geen gegevens | |
| President of Performance Suite | no data | geen gegevens | geen gegevens |
3.7yrs
Gemiddelde duur
40.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van EVH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 6.6yrs | US$8.93m | 0.27% $ 3.6m | |
| Independent Director | 4.8yrs | US$260.25k | 0.036% $ 485.8k | |
| Independent Director | 1.4yrs | US$245.50k | 0.0059% $ 78.3k | |
| Independent Director | less than a year | geen gegevens | 0.0053% $ 70.1k | |
| Independent Chairperson of the Board & Lead Independent Director | 9yrs | US$347.75k | 0.038% $ 507.5k | |
| Independent Director | 13.3yrs | US$265.25k | 0.048% $ 638.4k | |
| Independent Director | 7.2yrs | US$255.25k | 0.035% $ 467.0k | |
| Independent Director | 3.8yrs | US$265.25k | 0.018% $ 246.5k | |
| Independent Director | 3.9yrs | US$257.50k | 0.019% $ 257.8k | |
| Independent Director | 1.3yrs | US$195.83k | 0% $ 0 |
4.4yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van EVH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).